Besides EGFR(p.T790M), a range of driver and resistance mutations/aberrations, including ALK, ROS1, and RET rearrangements, HER2 insertions, and MET amplification have been identified in pretreatment plasma of progressive NSCLC patients by NGS with 100% specificity and 77% sensitivity (170). This evidence concerns the gene EGFR and non-small cell lung carcinoma.